 |
41 Diseases |  |
16 Trials |
|
16 Trials |  |
501 News |  |
| 12345678» |
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Journal, Surgery: Grade 3 Pancreatic Neuroendocrine Tumor Refractory to Chemotherapy Successfully Treated with Peptide Receptor Radionuclide Therapy Leading to Conversion Surgery. (Pubmed Central) - Mar 2, 2025
A 59-year-old woman was diagnosed with a pancreatic neuroendocrine tumor (P-NET; grade 3, Ki67: 25%) with multiple liver and lymph node metastases and started chemotherapy with streptozosin (500 mg/m2/day) in combination with lanreotide acetate (120 mg)...As PRRT was remarkably successful and the tumor shrank, surgery was performed to resect the primary pancreatic tumor, liver metastases, and lymph node metastases. CT evaluation performed six months after the surgery showed a complete response.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Preclinical, Journal: Hydroxypropyl ? Cyclodextrins Effects on Self-Assembly of Cyclic Peptide, Lanreotide Acetate, in Water and Subsequent Release rate from an in vitro Emulator of Subcutaneous Delivery. (Pubmed Central) - Feb 19, 2025
This complexation also alters the viscosity behavior of lanreotide from non-Newtonian under low shear rates to Newtonian solution. Furthermore, the lanreotide/ HP?CyD inclusion complex reduces interactions with hyaluronic acid in the subcutaneous environment, leading to significant improvement in the release rate of lanreotide acetate at high concentrations (above 3% w/w in water).
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Journal: ?-Cyclodextrin Derivatives Bind Aromatic Side Chains of the Cyclic Peptide Lanreotide. (Pubmed Central) - Feb 19, 2025
In this study, the inclusion complexes of the cyclic peptide drug lanreotide acetate with two common ?-cyclodextrin derivatives, Sulfobutyl ether ?-CD (SBE?-CD) and hydroxypropyl ?-CD (HP?-CD) were investigated...Docking studies suggested that the 1:1 inclusion complex is more favorable than higher order complexes due to the steric hindrance and size considerations. The docking analysis indicated the stable conformation of all three aromatic side chains with both ?-cyclodextrin derivatives, SBE?-CDand HP?-CD.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Somatuline LA (lanreotide suspension intramuscular) / Ipsen
New P3 trial: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov) - Feb 4, 2025
P3, N=274, Not yet recruiting, Sponsor: SWOG Cancer Research Network
- ||||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Real-world evidence: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (clinicaltrials.gov) - Jan 31, 2025
P=N/A, N=129, Completed, Sponsor: Ipsen
The docking analysis indicated the stable conformation of all three aromatic side chains with both ?-cyclodextrin derivatives, SBE?-CDand HP?-CD. Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion: AIM-NETs: Asian Investigation of Lanreotide Autogel (clinicaltrials.gov) - Jan 28, 2025
P=N/A, N=71, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Retrospective data, Journal: IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly. (Pubmed Central) - Dec 26, 2024
Our results demonstrated that initial IGF-I levels during SD-Lanreotide predicted the biochemical outcome after 12 months of HF-Lanreotide. Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen.
- |||| Oclaiz (octreotide subcutaneous depot) / Camurus
Trial completion date, Trial primary completion date: SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) - Dec 13, 2024
P3, N=332, Active, not recruiting, Sponsor: Camurus AB
Patients in whom HF-Lanreotide did not normalize IGF-I after 6 months of treatment remained uncontrolled 12 months after starting this regimen. Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Journal: Pachydermoperiostosis Due to a Novel HPGD Splicing Site Mutation Masquerading as Acromegaly. (Pubmed Central) - Dec 11, 2024
Reverse transcription polymerase chain reaction confirmed that this variant led to defective splicing with skipping of exon 6, a frameshift, and truncation at codon 13 of exon 7 downstream. His symptoms did not respond well to nonsteroidal anti-inflammatory drugs but showed excellent response to a trial of lanreotide autogel that has been used for about 1 year.
- || sunitinib / Generic mfg.
Clinical, P2 data, Journal, Metastases: SUNLAND: a randomized, double-blinded phase II GERCOR trial of sunitinib versus placebo and lanreotide in patients with advanced progressive midgut neuroendocrine tumors. (Pubmed Central) - Nov 20, 2024
P1
While we cannot entirely rule out the efficacy of sunitinib, lanreotide alone may play a significant role. EudraCT: 2012-001098-94.
- ||| Oclaiz (octreotide subcutaneous depot) / Camurus
Clinical, P3 data, Journal: Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. (Pubmed Central) - Oct 8, 2024
P3
CAM2029 provides a convenient and effective treatment option for acromegaly, with superior biochemical control versus placebo. Symptom control, QoL and satisfaction were improved from baseline SoC.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. (Pubmed Central) - Sep 24, 2024
Our long-term experience with octreotide and lanreotide in NET did not reveal differences in antitumor effectiveness. This is consistent with previous reports and might suggest that both SSA can be used interchangeably if needed.
- || Review, Journal: Medical treatment of acromegaly - When the tumor size matters: A narrative review. (Pubmed Central) - Sep 15, 2024
Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Clinical trial: The effectiveness of long-acting somatostatin analogue for output reduction of high-output intestinal fistula or small bowel enterostomy. A randomised controlled trial. (Pubmed Central) - Aug 27, 2024
P3/4
In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB). In patients with a high-output fistula or small bowel enterostomy, addition of lanreotide to current standard treatment can provide a clinically relevant output reduction.
- |||||| Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment open, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Aug 26, 2024
P3, N=288, Recruiting, Sponsor: RayzeBio, Inc.
In patients with a high-output fistula or small bowel enterostomy, addition of lanreotide to current standard treatment can provide a clinically relevant output reduction. Active, not recruiting --> Recruiting
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
P3 data, Journal, Metastases: Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study. (Pubmed Central) - Jul 22, 2024
P3
Patients' quality of life did not deteriorate and LAN was well tolerated. Although recruitment stopped early and the predefined sample size was not met, SPINET is the largest prospective study to date of SSA therapy in SSTR positive TCs and ACs and suggests clinical benefit in TCs.
- | Innohep (tinzaparin) / LEO Pharma, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Carcinoid Heart Disease and a Complicated Course of Progressive Gastroenteropancreatic Neuroendocrine Neoplasia: A Case Report. (Pubmed Central) - Jul 17, 2024
He was on treatment with subcutaneous lanreotide 120 mg twice weekly prior to admission...The patient was started on IV furosemide 40 mg twice daily, SC octreotide 100 ?g three times daily, and therapeutic tinzaparin...This case report highlights the importance of regular echocardiogram and cardiovascular checkups in patients with carcinoid tumours and liver metastases. A multidisciplinary approach involving medical oncologists, cardiothoracic surgeons, and cardiologists is vital in ensuring early treatment and preventing late-stage complications of carcinoid heart disease.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion date, Trial primary completion date, Metastases: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 4, 2024
P1/2, N=49, Recruiting, Sponsor: National Health Research Institutes, Taiwan
A multidisciplinary approach involving medical oncologists, cardiothoracic surgeons, and cardiologists is vital in ensuring early treatment and preventing late-stage complications of carcinoid heart disease. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Review, Journal: An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors. (Pubmed Central) - Jun 7, 2024
The findings highlight the overall safety of lanreotide autogel in the management of NETs, with a focus on its efficacy in controlling hormone secretion, tumor progression, and symptom management. New safety concerns and precautions are also addressed to assist healthcare providers in making informed decisions when prescribing lanreotide autogel.
- ||||| Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment closed, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Apr 28, 2024
P3, N=288, Active, not recruiting, Sponsor: RayzeBio, Inc.
New safety concerns and precautions are also addressed to assist healthcare providers in making informed decisions when prescribing lanreotide autogel. Recruiting --> Active, not recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion, Enrollment change: Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy (clinicaltrials.gov) - Apr 17, 2024
P4, N=3, Completed, Sponsor: Sheba Medical Center
Recruiting --> Active, not recruiting Unknown status --> Completed | N=10 --> 3
- ||||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Enrollment closed, Enrollment change, Real-world evidence: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (clinicaltrials.gov) - Apr 2, 2024
P=N/A, N=129, Active, not recruiting, Sponsor: Ipsen
Unknown status --> Completed | N=10 --> 3 Recruiting --> Active, not recruiting | N=210 --> 129
- octreotide subcutaneous depot (CAM2029) / Camurus
A RANDOMIZED PHASE 3 TRIAL TO ASSESS EFFICACY AND SAFETY OF A NOVEL FORMULATION OF OCTREOTIDE SUBCUTANEOUS DEPOT IN PATIENTS WITH ACROMEGALY (Umm Al Quwain hall) - Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_595;
P3
In this phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT04076462), patients on stable treatment with octreotide LAR or lanreotide autogel, and with normal IGF-1 levels at screening, were randomized 2:1 to once-monthly CAM2029 20 mg or placebo for 24 weeks. CAM2029 treatment resulted in robust biochemical control superior to placebo, substantially improved PROs compared to baseline SoC and placebo, and a safety profile consistent with SoC somatostatin receptor ligand treatments, demonstrating the potential of CAM2029 as an alternative to SoC acromegaly treatments that addresses unmet patient needs.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK. (Pubmed Central) - Feb 29, 2024
CAM2029 treatment resulted in robust biochemical control superior to placebo, substantially improved PROs compared to baseline SoC and placebo, and a safety profile consistent with SoC somatostatin receptor ligand treatments, demonstrating the potential of CAM2029 as an alternative to SoC acromegaly treatments that addresses unmet patient needs. Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference.
- ||||| Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment closed: SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) - Jan 25, 2024
P3, N=332, Active, not recruiting, Sponsor: Camurus AB
Almost all patients preferred to receive LAN treatment at home rather than in hospital with increased convenience and psychological benefits reported as key reasons for this preference. Recruiting --> Active, not recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
P2 data, Journal: Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study. (Pubmed Central) - Jan 11, 2024
P2
Recruiting --> Active, not recruiting LAN plus TMZ is a treatment option for patients with progressive GEP-NET with more aggressive biological profile showing a manageable safety profile.
- |||| Actinium-225 DOTATATE (RYZ101) / BMS
Trial completion date, Trial primary completion date, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Dec 22, 2023
P3, N=288, Recruiting, Sponsor: RayzeBio, Inc.
- cholestyramine (A3384) / Ipsen, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sutent (sunitinib) / Pfizer
Diarrhea is not a VIP guest (Sancy - Hilton Antwerp Old Town) - Dec 19, 2023 - Abstract #BWG2024BWG_45;
A combination of treatment with loperamide, pancreatic enzyme supplementation and codein syrup resulted in a mild reduction in diarrhea...For liver-dominant disease, targeted treatment is recommended, such as bland embolization, radiofrequency ablation, and radioembolization. Other treatments such as Everolimus, Sunitinib, peptide receptor radionuclide therapy (PRRT) or chemotherapy are alternatives for metastatic or unresectable disease.
- || metformin / Generic mfg.
P1 data, Clinical Trial,Phase I, Journal, Metastases: Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2. (Pubmed Central) - Dec 19, 2023
Among exploratory analyses, the presence of tumor genomic alterations in DNA damage pathways was associated with trend towards worse PFS, whereas a precocious reduction of HOMA-IR index and plasma cholesterol concentration showed a trend towards an association with better PFS. In conclusion, metformin plus lanreotide ATG is a safe and well tolerated combination treatment that is associated with promising antitumor activity in both non-diabetic and diabetic patients with WDNETs, and that warrants further investigation in larger clinical trials.
- || octreotide 3-month extended release (Debio 4126) / Debiopharm
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Nov 29, 2023
P1, N=30, Active, not recruiting, Sponsor: Debiopharm International SA
In conclusion, metformin plus lanreotide ATG is a safe and well tolerated combination treatment that is associated with promising antitumor activity in both non-diabetic and diabetic patients with WDNETs, and that warrants further investigation in larger clinical trials. Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Nov 2024
- || Actinium-225 DOTATATE (RYZ101) / BMS
Phase classification, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Nov 18, 2023
P3, N=288, Recruiting, Sponsor: RayzeBio, Inc.
Recruiting --> Active, not recruiting | Phase classification: P1b --> P1 | Trial completion date: Jun 2025 --> Dec 2024 | Trial primary completion date: May 2025 --> Nov 2024 Phase classification: P1b --> P3
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal, HEOR, Real-world evidence, Adherence, Real-world: Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. (Pubmed Central) - Sep 14, 2023
Patients with more comorbidities had more health care visits during the first year after diagnosis, suggesting increased disease burden. Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy.
- || Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment change, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Sep 1, 2023
P1b, N=288, Recruiting, Sponsor: RayzeBio, Inc.
Real-world evidence on treatment patterns provides insights into recommendations for individualized therapy. N=218 --> 288
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3). (Pubmed Central) - Aug 7, 2023
Nurses strongly preferred the user experience of the Somatuline Autogel syringe over the Lanreotide Pharmathen syringe. "Ease of use" and "comfortable to handle" were the most important syringe attributes, and performance rating was significantly higher with Somatuline Autogel versus Lanreotide Pharmathen syringe for all but one attribute.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial primary completion date: AIM-NETs: Asian Investigation of Lanreotide Autogel (clinicaltrials.gov) - Jul 22, 2023
P=N/A, N=95, Recruiting, Sponsor: Asan Medical Center
"Ease of use" and "comfortable to handle" were the most important syringe attributes, and performance rating was significantly higher with Somatuline Autogel versus Lanreotide Pharmathen syringe for all but one attribute. Trial primary completion date: Jan 2023 --> Jan 2024
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal, Real-world evidence, Real-world: Real world use of lanreotide in neuroendocrine tumors. (Pubmed Central) - Jul 12, 2023
Standard starting dose of lanreotide 120 mg every 28 days was used in 66 patients...Overall, our findings were in keeping with current guidelines. It will be interesting to assess how clinical practice evolves in the future and to determine the role of dose escalation for disease control.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Journal: Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey. (Pubmed Central) - Jul 3, 2023
Most patients did not experience anxiety prior to their most recent injection and acknowledged that thanks to their treatment they had a good quality of life despite their disease. Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs.
- | octreotide 3-month extended release (Debio 4126) / Debiopharm
Trial completion date, Trial primary completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - May 31, 2023
P1b, N=30, Recruiting, Sponsor: Debiopharm International SA
Most strongly agreed that the PSP met their medical needs, which highlights the valuable service that LAN PSPs provide for patients with NETs. Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> May 2025
- octreotide chloride FluidCrystal Injection depot (CAM2029) / Novartis
Randomized, Placebo-Controlled Phase 3 Trial Protocol Assessing the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Acromegaly (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_937;
P3
Key exclusion criteria included GH ?2.5 ?g/L at screening, pituitary surgery within 6 months of screening, prior pituitary irradiation, and recent treatment with pasireotide, pegvisomant, or dopamine agonists...The estimated primary completion date for the trial is May 2023. After completing study treatment, patients may switch to open-label treatment in a phase 3 long-term safety and extension trial of CAM2029 (NCT04125836).
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
PRESTO 3: A Simulated-Use Study Assessing Preferences of Nurses in the USA and Europe Between Two Lanreotide Syringes (Somatuline Autogel vs Pharmathen) (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_929;
The attribute considered least important was 'fast administration from preparation to injection' (Europe, 26.5%; USA, 26.9%).ConclusionsThis simulated-use study showed that nurses both in the USA and Europe strongly preferred the user experience of the Somatuline Autogel syringe over the Pharmathen syringe, and ranked theSomatuline Autogel syringe more highly across almost all attributes. Ease of use and handling comfort were considered the most important to nurses in both regions.
- Treatment Patterns in Acromegaly: Analysis of Real-World US Insurance Claims from the MarketScan (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_928;
Only 7 patients received second-generation SRL pasireotide and no patients received oral octreotide in LOT 1...Lancet Diabetes Endocrinol. 2022
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
SUBCUTANEOUS SELF-INJECTIONS OF LANREOTIDE IS A GOOD ALTERNATIVE FOR ACROMEGALIC PATIENTS WITH LONG COVID TREATED WITH ANTICOAGULANTS (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_906;
Telemedicine was a feasible tool in acromegalic patients with Long Covid. The replacement of intramuscular injections of Octreotide LAR for Lanreotide Autogel self injected subcutaneously allowed stability of disease control and provided an alternative to injections administered in the health care
- cabergoline / Generic mfg.
Novel Approach To Management of Acromegaly with De Novo Oral Octreotide Or Combination Therapy with Cabergoline: A Case Series (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_905;
First line medical therapy consists of first-generation injectable somatostatin receptor ligands (SRL) (octreotide LAR, lanreotide autogel)...If IGF-1 levels do not normalize, pasireotide or pegvisomant can be tried...The dose was increased to 80 mg daily are lab results are pending. These are the first two published cases describing a novel approach to treating acromegaly in which patients were found to have a biochemical response to de novo oral octreotide either alone or combined with cabergoline.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada. (Pubmed Central) - Apr 24, 2023
These are the first two published cases describing a novel approach to treating acromegaly in which patients were found to have a biochemical response to de novo oral octreotide either alone or combined with cabergoline. These findings provide valuable insight into SSA use in clinical settings and may inform treatment selection.
- ||| Actinium-225 DOTATATE (RYZ101) / BMS
Enrollment open, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Apr 21, 2023
P1b, N=218, Recruiting, Sponsor: RayzeBio, Inc.
These findings provide valuable insight into SSA use in clinical settings and may inform treatment selection. Active, not recruiting --> Recruiting
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
Yo quisiera saber qué ocurre con esos medicamentos. Lo primero. Por qué se ha cambiado de Somatuline autogel a Myrelez? Este cambio ha generado más que inquietud en las personas que como mi madre, necesitan de ése tratamiento para sobrevivir. No me cuadra calidad - precio. (Twitter) - Apr 20, 2023
- | paltusotine (CRN00808) / Crinetics
Journal: ACROBAT Edge: Safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. (Pubmed Central) - Apr 14, 2023
These results suggest once-daily oral paltusotine was effective in maintaining IGF-I values in patients with acromegaly who switched from injected SRLs. Paltusotine was well tolerated with a safety profile consistent with other SRLs.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Apr 12, 2023
P4, N=53, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Paltusotine was well tolerated with a safety profile consistent with other SRLs. Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023 | Trial primary completion date: Sep 2024 --> Apr 2023
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Enrollment open, Metastases: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Apr 7, 2023
P1/2, N=49, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Apr 2023 | Trial primary completion date: Sep 2024 --> Apr 2023 Not yet recruiting --> Recruiting
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
Trial completion date, Real-world evidence: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (clinicaltrials.gov) - Mar 16, 2023
P=N/A, N=210, Recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting Trial completion date: May 2025 --> Dec 2024